MedTrace Logo

Neurofilaments for NEDA Assessing in MS

NCT03250169 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2022-02-25

No results posted yet for this study

Summary

Goal is to evaluate the achievement of biological NEDA as demonstrated by a drop in neurofilament levels in MS patients commencing Alemtuzumab therapy as part of their MS management.

Conditions

Interventions

DRUG

Alemtuzumab

Licensed dose

Sponsors & Collaborators

  • Queen Mary University of London

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2022-01-28
Completion
2022-01-28
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03250169 on ClinicalTrials.gov